Do some of your patients with dry eye disease deserve a change?
IN THIS SECTION
Do some of your patients with dry eye disease deserve a change?
In a previous survey, how many millions of Americans were estimated to be diagnosed with dry eye disease?
In 2016, how many dry eye disease patients were estimated to be treated with a prescription?
Between 2005 and 2012, how much did the prevalence of dry eye disease increase?
FOOTNOTES
*Due to combination use, the number of patients treated by prescription will overstate the actual number of treated patients. Data were compiled by Jefferies Equity Research analysts employed in the United States by Jefferies LLC, a firm registered with the Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority, Inc. Jefferies does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report.
†Retrospective analysis to assess overall prevalence, annual prevalence, and incidence of DED using the DOD MHS data on beneficiary medical claims from US DOD military and civilian facilities from January 1, 2003, through March 31, 2015. Analysis (2005-2012) was conducted on a total of 9,732,272 MHS beneficiaries, aged 2-80+. The analysis of prevalence and incidence was estimated based on ICD-9 and current procedural terminology (CPT) codes and prescription fills.
DOD=Department of Defense, MHS=Military Health System.
*Due to combination use, the number of patients treated by prescription will overstate the actual number of treated patients. Data were compiled by Jefferies Equity Research analysts employed in the United States by Jefferies LLC, a firm registered with the Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority, Inc. Jefferies does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report.
†Retrospective analysis to assess overall prevalence, annual prevalence, and incidence of DED using the DOD MHS data on beneficiary medical claims from US DOD military and civilian facilities from January 1, 2003, through March 31, 2015. Analysis (2005-2012) was conducted on a total of 9,732,272 MHS beneficiaries, aged 2-80+. The analysis of prevalence and incidence was estimated based on ICD-9 and current procedural terminology (CPT) codes and prescription fills.
DOD=Department of Defense, MHS=Military Health System.
Dry eye disease is a multifactorial disease that may be progressive and chronic.
Some patients may require more than artificial tears.4-9
Inflammation: a possible underlying cause of dry eye disease8
The American Academy of Ophthalmology suggests that inflammation may be an underlying cause of your patient's dry eye disease. Dry eye disease can be triggered by a variety of proposed factors, including7,8,10:
Contact lenses
Antihistamines
Prolonged device
time
Sex (women may be at higher risk)
Aging
Low humidity, cold,
or windy places
Changes in
hormones
Reading a lot
Xiidra is a unique prescription eye drop specifically designed to inhibit inflammation in dry eye disease.11
The exact mechanism of action of Xiidra in dry eye disease is not known.
Inflammation: a possible underlying cause of dry eye disease8
The American Academy of Ophthalmology suggests that inflammation may be an underlying cause of your patient’s dry eye disease. Dry eye disease can be triggered by a variety of proposed factors, including7,8,10:
Contact lenses
Antihistamines
Prolonged device
time
Sex (women may be at higher risk)
Aging
Low humidity,
cold, or windy
places
Changes in
hormones
Reading a lot
Xiidra is a unique prescription eye drop specifically designed to inhibit inflammation in dry eye disease.11
The exact mechanism of action of Xiidra in dry eye disease is not known.
Common symptoms of dry eye disease8
If your patients are experiencing persistent dry eye symptoms and artificial tears aren’t enough, consider prescribing Xiidra, which was designed to target a source of underlying inflammation that may fuel dry eye disease.4-6,11-13§
§Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.6,11,12
Xiidra may provide lasting symptom relief
in as early as 2 weeks11¶
Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.11
¶The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.11